After evaluating the standalone profile of Teva's generic and brand businesses, JPMorgan analyst Chris Schott does not see a strong valuation rationale for a break-up of the company. In a research note to investors, Schott says he does not see a "compelling enough profile" within Teva's branded business to support meaningful valuation upside, and he believes a generic multiple re-rating is unlikely in the current environment. The analyst keeps a Neutral rating on Teva with a $37 price target.

Vanda Pharmaceuticals "announced that the Supreme Court denied Vanda's petition for a writ of certiorari in its HETLIOZ(R) Abbreviated New Drug Application litigation against Teva Pharmaceuticals USA, Inc., Apotex Inc. and Apotex Corp." CEO Mihael H. Polymeropoulos stated: "We are disappointed that the Supreme Court has decided not to hear our case and clarify the lower court standard for obviousness in patent law. However, we are pleased that our case has drawn attention to an area of law that has broad and significant implications in life sciences innovation."